Cardiovascular Stem Cell TherapyResults

A total number of 21 patients with heart complications were put under observation after the ischemic heart disease therapy.

A whopping 88% of the patients showed clinical improvements.

Few of the various improvements reported were - less shortness of breath, reduction in medication, less weakness, less tiredness and less edema. In one case the pacemaker could be turned down.

The average percentage of development of the Left Ventricular Ejection Fraction (LVEF) which is a measure of the heart function was 24.2%.

Percentage improved heart disease patients

Improvement No Change

100%

80%

60%

40%

20%

0%

Improvements of LVEF

LVEF - values before and after treatment

1 2 3 4 5 6 7 8 9 10 11 12 13

1 2 3 4 5 6 7 8 9 10 11 12 13 14

Mean LVEF increase

100%90%80%70%60%50%40%30%20%10%0%

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

Delta%

Delta% After

LEVF befor and after ASCT01 treatment

Before After

45%

40%

35%

30%

25%

20%

15%

Results From Adipose Derived StemCells

Methods :-• 60 cc’s adipose tissue removed via local tumescent

anesthesia • Fat washed to remove red blood cells • Enzymatic digestion with Adipolase • Centrifugation to separate stromal vascular fraction • Washing and filtration • Cell delivered to patient

Criteria :- • Intramyocardial delivery via MyoCath catheter • Number and frequency Of adverse events • Changes in left ventricular ejection fraction (LVEF) • Exercise capability • Quality Of life

Results :-• 615 patients treated • Average improvement Of Il points in LVEF • Average increase of 128 meters in 6 minute walk exercise capacity test

Bioheart MyoCathTM

Trial ICongestive Heart Failure

Baseline 3 Month

100%90%80%70%60%50%40%30%20%10%

p = 0.04, N = 5

%LV

EF

Baseline 3 Month

600

550

500

450

400

p = 0.04, N = 5

Dis

tanc

e (M

eter

s)

Left Ventricular Ejection Fraction Exercise Capacity - Six Minute Walk Distance

Conclusions :-• Adipose tissue is readily available and a plentiful source Of Stem cells • Preliminary data for COPO CHF and wound healing demonstrates strong safety profile in patients. • ADSCs can be utilized in degenerative diseases to promote reduction of inflammation and healing.

Trial IIANGEL TRIAL

Product Specifications :-• ADSC from 60 cc’s Of fat processed at point Of Care in 35 minutes • Delivered intra-myocardiany Via Catheter in 4 ml Saline

Co - Primary Efficacy Endpoints :- • Exercise capacity (6 min walk test) • Quality of life (MLFHF)

Secondary Efficacy Endpoints :-• Ejection Fraction

Left Ventricular Election Fraction

Ejection Fraction

Per

cenr

age

50%45%40%35%30%25%20%15%10%5%0%

Baseline

3 Month

6 Month

100 101 102 103 104

Baseline 40% 20% 40% 39% 39%

3 Month 40% 30% 42% 42% 33%

6 Month 45% 35% 45% 45% 44%

Base line (N = 5)

3 Month (N = 5)

6 Month (N = 5)

P = 0.01

P = 0.17

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

Minnesota Living with Heart Failure

MLWHF Scores

Per

cenr

age

100%90%80%70%60%50%40%30%20%10%0%

Baseline

3 Month

6 Month

pt 100 pt 101 pt 102 pt 103 pt 104

Baseline 61% 55% 13% 62% 25%

3 Month 13% 47% 4% 58% 32%

6 Month 19% 34% 18% 47% 42%

Exercise Capacity

Distance 8MW

Per

cenr

age

600550500450400350300250200150100500

Baseline

3 Month

6 Month

100 101 102 103 104

Baseline 158 385 485 180 260

3 Month 295 450 550 200 240

6 Month 305 465 450 290 270

Base line (N = 5)

3 Month (N = 5)

6 Month (N = 5)

P = 0.01

P = 0.17

600550500450400350300250200150100500